Beam Therapeutics Reports Initial BEAM-301 Phase 1/2 Clinical Data
Beam Therapeutics reported initial clinical data from the BEAM-301 trial, describing proof of concept for genetic correction in GSDIa. In the 40 mg cohort, two patients achieved 15 hours of controlled fasting.
Story updates
11:02:48 AM UTC
SquawkNews
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proo